证券代码：300244 证券简称：迪安诊断 公告编号：2025-037 迪安诊断技术集团股份有限公司 2025 年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 10 月 23 日 1 巨潮资讯网网址：http://www.cninfo.com.cn/ 特此公告。 迪安诊断技术集团股份有限公司 董事会 特别提示：本公司 2025 年第三季度报告于 2025 年 10 月 24 日在中国证监 会指定的创业板信息披露网站上披露，敬请投资者注意查阅。 迪安诊断技术集团股份有限公司（以下简称"公司"）于 2025 年 10 月 22 日召开第五届董事会第十六次会议，审议通过了《关于<2025 年第三季度报告> 的议案》。为使投资者全面了解公司的经营成果、财务状况及未来发展规划，公 司《2025 年第三季度报告》于 2025 年 10 月 24 日在中国证监会指定的创业板 信息披露网站巨潮资讯网上披露，敬请投资者注意查阅。 ...

Financial Performance - The company's revenue for Q3 2025 was ¥2,629,101,734.09, a decrease of 13.52% compared to the same period last year[5] - Net profit attributable to shareholders was ¥46,427,604.81, down 21.46% year-on-year, while the net profit excluding non-recurring gains and losses was ¥44,787,340.40, a decrease of 23.94%[5] - For the first nine months of 2025, the company achieved a total revenue of ¥7,565,586,728.42, representing an 18.28% decline year-on-year[9] - Total operating revenue for the current period is ¥7,565,586,728.42, a decrease of 18.3% from ¥9,258,110,867.57 in the previous period[21] - Net profit for the current period is ¥182,010,837.30, a decline of 39.9% compared to ¥302,683,796.72 in the previous period[22] - Earnings per share (basic) for the current period is ¥0.0928, down from ¥0.2118 in the previous period[22] - The company’s total profit before tax is ¥276,089,133.22, down from ¥424,171,620.41 in the previous period, representing a decline of 34.8%[22] - The company’s total comprehensive income for the current period is ¥182,010,837.30, compared to ¥302,682,117.22 in the previous period[22] Cash Flow and Assets - The company reported a significant increase in net cash flow from operating activities, reaching ¥871,715,623.10, a rise of 1508.33% compared to the previous year[9] - Operating cash flow for the current period is ¥871,715,623.10, a significant increase from ¥54,200,047.93 in the previous period, reflecting a strong operational performance[24] - Total cash inflow from operating activities decreased to ¥8,468,610,339.97 from ¥9,601,233,221.75, indicating a decline of approximately 11.8% year-over-year[24] - Cash outflow from operating activities also decreased to ¥7,596,894,716.87 from ¥9,547,033,173.82, resulting in a reduction of about 20.4%[24] - The ending cash and cash equivalents balance is ¥1,346,814,696.43, a slight decrease from ¥1,352,553,738.03 in the previous period[25] - The company’s cash flow from operating activities reflects a robust operational strategy despite a decrease in total cash inflows[24] Shareholder Information - Total number of common shareholders at the end of the reporting period was 45,695[12] - The largest shareholder, Chen Haibin, holds 26.31% of shares, totaling 164,438,933 shares, with 76,460,000 shares pledged[12] - The company repurchased 13,880,000 shares, accounting for 2.22% of the total share capital[13] - The number of shares held by the top ten unrestricted shareholders totaled 100,000,000 shares[13] Asset and Liability Management - Total assets at the end of the reporting period were ¥14,765,016,764.23, a decrease of 6.47% from the previous year[5] - The company's total current assets decreased from CNY 11,902,542,869.23 to CNY 11,040,261,948.58, a decline of approximately 7.24%[18] - Cash and cash equivalents decreased from CNY 1,830,317,273.55 to CNY 1,372,146,968.42, a reduction of about 25%[18] - Accounts receivable decreased from CNY 7,258,897,680.33 to CNY 6,735,971,949.60, a decline of approximately 7.2%[18] - Total liabilities amount to ¥6,090,797,605.65, a decrease from ¥7,018,794,162.32 in the previous period[20] - Total equity is ¥8,674,219,158.58, down from ¥8,767,189,572.23 in the previous period[20] - The company’s long-term borrowings decreased to ¥1,348,014,472.00 from ¥1,593,720,736.00, a reduction of 15.4%[20] Operational Developments - The company added 12 new precision centers in the first three quarters, bringing the total to 102, with related business growth of 11.25%[10] - The company signed 1,504 new clients, further increasing its market share[10] - The company is advancing its AI products and digital solutions, collaborating with partners like Alibaba and Huawei Cloud, and has become a key player in the trusted data space in Hangzhou[10] - Financial expenses decreased by 36.56% during the reporting period, reflecting improved internal management efficiency[10] Research and Development - The company reported a decrease in research and development expenses to ¥169,463,374.03 from ¥225,278,980.27, a reduction of 24.8%[21]

Core Insights - The company reported a third-quarter revenue of 2.629 billion yuan, a decrease of 13.52% [1] - Net profit for the third quarter was 46.4276 million yuan, down 21.46% [1] - For the first three quarters, revenue totaled 7.566 billion yuan, reflecting an 18.28% decline [1] - Net profit for the first three quarters was 56.7048 million yuan, a significant drop of 56.67% [1] Financial Performance - Third-quarter revenue: 2.629 billion yuan, down 13.52% [1] - Third-quarter net profit: 46.4276 million yuan, down 21.46% [1] - Year-to-date revenue: 7.566 billion yuan, down 18.28% [1] - Year-to-date net profit: 56.7048 million yuan, down 56.67% [1]

Core Insights - On October 20, Dian Diagnostics experienced a 1.00% increase in stock price with a trading volume of 99.02 million yuan [1] - The company reported a financing buy-in of 10.20 million yuan and a net financing outflow of -2.76 million yuan on the same day [1] - As of October 20, the total financing and securities lending balance for Dian Diagnostics was 610 million yuan, indicating a high level of financing activity [1] Financing Summary - On October 20, Dian Diagnostics had a financing buy-in of 10.20 million yuan, with a current financing balance of 608 million yuan, representing 6.44% of its market capitalization [1] - The financing balance is above the 70th percentile of the past year, indicating a relatively high level of financing [1] - In terms of securities lending, there were no shares repaid, with 1,200 shares sold, amounting to 18,100 yuan at the closing price [1] Company Overview - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, is based in Hangzhou, Zhejiang Province [1] - The company specializes in providing medical diagnostic services, focusing on outsourcing solutions for various healthcare institutions, including hospitals and health service centers [1] - The revenue composition includes 65.34% from channel products and 34.66% from diagnostic services [1] Financial Performance - As of June 30, 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61% [2] - The net profit attributable to shareholders was 10.28 million yuan, reflecting a significant year-on-year decline of 85.68% [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.32% to 48,300, while the average number of circulating shares per person increased by 12.77% to 10,376 shares [2] - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed over the past three years [3] - Notable institutional shareholders include Hong Kong Central Clearing Limited and new entrant招商优势企业混合A, indicating a shift in shareholder composition [3]

Core Viewpoint - The stock of Dian Diagnostics has experienced a decline recently, with a notable drop in trading volume and a significant decrease in revenue and profit year-on-year [1][2]. Financial Performance - As of June 30, 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61% [2]. - The net profit attributable to shareholders was 10.2772 million yuan, reflecting a substantial year-on-year decrease of 85.68% [2]. - The stock price has increased by 35.78% year-to-date, but has seen declines of 5.81% over the last five trading days, 12.22% over the last 20 days, and 3.77% over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.32% to 48,300, while the average circulating shares per person increased by 12.77% to 10,376 shares [2]. - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed over the last three years [3]. Institutional Holdings - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 14.7985 million shares, an increase of 3.4713 million shares from the previous period [3]. - The third-largest circulating shareholder is the newly entered招商优势企业混合A, holding 11 million shares [3]. - The seventh-largest shareholder, 南方中证1000ETF, increased its holdings by 872,500 shares to 4.6097 million shares [3].

Core Insights - On October 15, 2023, Dian Diagnostics saw a stock increase of 2.02% with a trading volume of 157 million yuan, indicating positive market sentiment towards the company [1] - The company reported a financing net buy of -594.83 million yuan on the same day, suggesting a higher level of selling pressure compared to buying [1] - As of October 15, 2023, the total balance of margin trading for Dian Diagnostics was 620 million yuan, which is relatively high compared to historical levels [1] Financing Summary - On October 15, 2023, Dian Diagnostics had a financing buy amount of 13.50 million yuan, while the financing balance stood at 617 million yuan, accounting for 6.32% of its market capitalization [1] - The financing balance is above the 70th percentile of the past year, indicating a high level of leverage [1] - The company had a short selling balance of 233.67 million yuan, with a short selling volume of 14.95 million shares, which is also above the 90th percentile of the past year [1] Financial Performance - For the first half of 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61% [2] - The net profit attributable to shareholders for the same period was 10.28 million yuan, reflecting a significant year-on-year decline of 85.68% [2] Shareholder Information - As of June 30, 2025, the number of shareholders for Dian Diagnostics was 48,300, a decrease of 11.32% from the previous period [2] - The average number of tradable shares per shareholder increased by 12.77% to 10,376 shares [2] - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed in the last three years [3]

Core Points - The company announced the appointment of Fang Yan as the representative for securities affairs [2] Group 1 - The board of directors of the company approved the hiring of Fang Yan [2]

Core Viewpoint - The stock price of Dian Diagnostics has shown a year-to-date increase of 38.48%, but has recently experienced a decline of 3.51% over the past five trading days and 13.55% over the past twenty days [2] Financial Performance - As of June 30, Dian Diagnostics reported a revenue of 4.936 billion yuan, representing a year-on-year decrease of 20.61%, and a net profit attributable to shareholders of 10.2772 million yuan, down 85.68% year-on-year [2] - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed over the past three years [3] Stock Market Activity - On October 14, the stock price fell by 2.04%, trading at 15.38 yuan per share with a total transaction volume of 171 million yuan and a turnover rate of 2.18%, resulting in a total market capitalization of 9.612 billion yuan [1] - The net outflow of main funds was 16.4086 million yuan, with large orders showing a buy of 28.2954 million yuan and a sell of 40.5438 million yuan [1] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 11.32% to 48,300, with an average of 10,376 circulating shares per person, an increase of 12.77% [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 14.7985 million shares, an increase of 3.4713 million shares from the previous period [3]

Group 1 - The core point of the article is the internal personnel adjustment at Dian Diagnostics, with the appointment of Fang Yan as the new securities affairs representative, replacing Zhu Disheng [1] - For the first half of 2025, the revenue composition of Dian Diagnostics is as follows: commercial revenue accounts for 73.72%, service revenue accounts for 30.66%, and internal related offsets account for -4.37% [1] - As of the time of reporting, the market capitalization of Dian Diagnostics is 9.8 billion yuan [1]

迪安诊断技术集团股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300244 证券简称：迪安诊断 公告编号：2025-034 因公司内部岗位调整，祝迪生先生不再担任公司证券事务代表职务。根据《公 司法》《深圳证券交易所上市公司自律监管指引第 1 号——业务办理》《公司章程》 《董事会秘书工作细则》等有关规定，为保障董事会工作的顺利开展，公司拟聘 任方勔女士为公司新任证券事务代表，任期自本次董事会会议审议通过之日起至 第五届董事会届满之日止。具体内容详见公司于同日在巨潮资讯网披露的《关于 变更证券事务代表的公告》。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 特此公告。 2025 年 10 月 13 日 1 2025 年 10 月 13 日 10 点，迪安诊断技术集团股份有限公司（以下简称"公 司"或"迪安诊断"）以通讯表决的方式召开了第五届董事会第十五次会议。召 开本次会议的通知已于 2025 年 10 月 10 日以短信、电子邮件等方式通知全体董 事。会议由公司董事长陈海斌先生召集和主持。本 ...